Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Michelle A. Worst"'
Autor:
Sarah Elizabeth Bomba, Emily S. Mikhael, Megan Whitney, Ahmad Sarris, Michelle Arielle Worst, Joseph R Mikhael
Publikováno v:
Blood. 140:13109-13110
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::327473b867e9fcdec38b2f439c8a163e
https://doi.org/10.1182/blood-2022-163599
https://doi.org/10.1182/blood-2022-163599
Autor:
Reem A. Shalabi, Michelle A. Worst, Thomas E. Hughes, Tracey Walsh‐Chocolaad, Lisa Cook, Kristen Gunn, Brian Wells, Rodica Ciurea, Georg Aue, Xin Tian, Richard W. Childs
Publikováno v:
British journal of haematologyReferences. 196(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b831d767978ac0fb70ece4d775a03413
https://pubmed.ncbi.nlm.nih.gov/34881432
https://pubmed.ncbi.nlm.nih.gov/34881432
Publikováno v:
Journal of Clinical Oncology. 40:e23004-e23004
e23004 Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare, heterogenous neoplasms characterized by a wide spectrum of clinical manifestations. Management strategies are varied and include surgery, radiological intervention,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00caa0a1fe82d2ca26ddbaff2b216036
https://doi.org/10.1200/jco.2022.40.16_suppl.e23004
https://doi.org/10.1200/jco.2022.40.16_suppl.e23004
Publikováno v:
Neuro Oncol
BACKGROUND Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic condition characterized by a wide spectrum of clinical findings. Patients with NF1 develop benign and malignant tumors along the nerves of the skin, brain, and other body part
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34955514c66e5756d9922ddbef3ceda1
https://europepmc.org/articles/PMC7651669/
https://europepmc.org/articles/PMC7651669/
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A664-A664
BackgroundMalignant pleural mesothelioma (MPM) is a rare and aggressive inflammatory cancer commonly associated with prior exposure to asbestos. Until recently, approved systemic treatments for MPM have been limited to chemotherapy regimens that have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f15daf73d0e7594c79cf03dea679f15d
https://doi.org/10.1136/jitc-2021-sitc2021.635
https://doi.org/10.1136/jitc-2021-sitc2021.635
Publikováno v:
Journal of Clinical Oncology. 39:e23008-e23008
e23008 Background: Although relatively rare, neurotrophic receptor tyrosine kinase (NTRK) fusions, represent a clinically relevant subgroup of NSCLC that can derive benefit from targeted therapies. Relatively quick and durable responses have been ach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bff3f7c9a5047a5c254894bfe9fb331
https://doi.org/10.1200/jco.2021.39.15_suppl.e23008
https://doi.org/10.1200/jco.2021.39.15_suppl.e23008
Publikováno v:
Journal of Clinical Oncology. 39:e23009-e23009
e23009 Background: Neurofibromatosis type 1 (NF1) is an uncommon complex autosomal dominant disorder caused by germline mutations in the NF1 tumor suppressor gene. Therapeutic options have historically been limited with surgical debulking being the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce7c195a4ec43f187a97cb0c18f4d7aa
https://doi.org/10.1200/jco.2021.39.15_suppl.e23009
https://doi.org/10.1200/jco.2021.39.15_suppl.e23009
Autor:
Michelle A. Worst, Katie Lucero
Publikováno v:
Clinical Cancer Research. 26:PO-073
Introduction: COVID-19 has the ability to make certain populations particularly vulnerable to infection, including those with cancer. Data relating to how the virus is transmitted, vulnerability, preventative measures, and treatment have evolved almo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e96c0c505a3e1b1bd6fe021506953bf
https://doi.org/10.1158/1557-3265.covid-19-po-073
https://doi.org/10.1158/1557-3265.covid-19-po-073
Publikováno v:
Cancer Research. 80:2040-2040
Background: Patients with advanced EGFR-mutated NSCLC benefit from treatment with EGFR TKIs. However, gaps in oncologists' performance hamper their ability to integrate individualized treatments into the care of patients with this disease. This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d1089d602c7c964002e6b638e1750a4
https://doi.org/10.1158/1538-7445.am2020-2040
https://doi.org/10.1158/1538-7445.am2020-2040
Autor:
Michelle Arielle Worst, Ann Carothers, Timothy F. Cloughesy, Giuseppe Lombardi, Lisa Brauer, Kinjal Parikh
Publikováno v:
Journal of Clinical Oncology. 38:11026-11026
11026 Background: Glioblastoma multiforme (GBM) is a rare, malignant tumor of the central nervous system (CNS) with poor prognosis. Nearly all patients experience recurrence due to GBM’s heterogeneity and there is currently no standard approach to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d216ab1c3dc2c5903f44d59ab424f71
https://doi.org/10.1200/jco.2020.38.15_suppl.11026
https://doi.org/10.1200/jco.2020.38.15_suppl.11026